Sethera Therapeutics

New article from @SetheraTx CEO, Karsten Eastman in this week's Drug Discovery News: Reimagining enzyme function for synthetic biology and drug discovery drugdiscoverynews.com/reimagining-en…

Recombinant polymacrocycles at scale: stability, selectivity, and new screening possibilities. Drug Discovery Online covers the tech behind Sethera’s enzyme-driven platform: drugdiscoveryonline.com/doc/how-sether… #Peptides #DrugDiscovery #Enzymology

Enzyme PapB could boost diabetes and obesity peptide drugs drugtargetreview.com/news/189749/en…

Check out our recent publication on enzymatic modification of GLP1 analogs! We think this is really exciting because it opens many unique doors for architectural changes in late-stage peptide development. pubs.acs.org/doi/10.1021/ac…

Sethera's first paper has released at PNAS. Check it out here! pnas.org/doi/10.1073/pn… #peptides #enzymes #science

We are thrilled to announce that Dr. Robert Langer has joined as Chair of our Scientific Advisory Board and that General Larry V. Lunt has joined our Board of Directors!

We’re thrilled to announce that Sethera has successfully closed our first fundraising round, raising $3M in capital. This funding will accelerate our efforts to further diversify the architectures of libraries we can generate through our proprietary enzymatic processes. By expanding these capabilities, we aim to unlock new therapeutic opportunities & address complex biological challenges with precision-engineered peptide therapeutics. Thank you to our investors and supporters who share our vision for advancing the boundaries of peptide science.

Follow @SetheraTx for new #peptide-based #therapeutics designed to engage multiple targets simultaneously, paving the way for innovative treatments for cancer and other challenging diseases.

Sethera Therapeutics is revolutionizing peptide-based drug development with our cutting-edge enzymatic cross-linking technology. setheratx.com